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Abstract
Background: Transcatheter aortic valve implantation (TAVI) can cause profound haemodynamic 
perturbation in the peri-operative period. Veno-arterial extracorporeal membrane oxygenation 
(ECMO) can be used to provide cardiorespiratory support during this time, either prophylactically or 
emergently.
Method: 100 TAVI procedures were performed between 2009 and 2013 in our institution. ECMO was 
used in 11 patients, including eight prophylactic and three rescue cases. Rescue ECMO was required 
for ventricular fibrillation after valvuloplasty, and aortic annulus rupture. The criteria for prophylactic 
ECMO included heart failure requiring stabilisation pre-TAVI, haemodynamic instability with balloon 
aortic valvuloplasty performed to improve heart function pre-TAVI, moderate or severe left and/or 
right ventricular failure, or borderline haemodynamics at procedure. Differences in preoperative 
characteristics and postoperative outcomes between ECMO and non-ECMO TAVI patients were 
compared, and significant results were further assessed controlling for EuroSCORE.
Results: Compared to TAVI patients who did not require ECMO, ECMO patients had significantly 
(p<.05) higher mean EuroSCORE (51 vs. 30%). Postoperative outcomes, however, were largely 
comparable between the two groups. All-cause mortality occurred in nil prophylactic ECMO patients, 
one rescue ECMO patient, and two non-ECMO patients. The difference in mortality between ECMO 
and non-ECMO patients was not significantly different (9 vs. 2%; p>.05). ECMO patients were more 
likely to develop acute renal failure than non-ECMO patients (36 vs. 8%, p<.05), which was most 
likely due to haemodynamic collapse and end-organ dysfunction in patients that required ECMO 
rescue.
Conclusions: Instituting prophylactic ECMO in selected very high-risk patients may help avoid 
consequences of intraoperative complications and the need for emergent rescue ECMO.
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Introduction
Transcatheter aortic valve implantation (TAVI) has been shown to be an effective method of treating 
severe aortic stenosis in patients who are deemed too high-risk for surgical aortic valve replacement 
[1]. Consequently TAVI patients generally have multiple comorbidities including coronary artery 
disease, peripheral vascular disease, renal insufficiency, and severely impaired ventricular function. 
Veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) can provide temporary 
cardiorespiratory support by performing the vital functions of haemodynamic support and 
oxygenation. It can be used in both an elective setting to provide prophylactic intraoperative support, 
or in emergent settings as rescue for low cardiac output. During the early phase of our institution’s 
TAVI program we have used both prophylactic and rescue ECMO during TAVI procedures in very 
high-risk patients. The aim of this study was to analyse the outcomes of these patients, and to 
determine whether prophylactic ECMO support can improve outcomes.
Methods
Data for TAVI patients at our institution (The Royal Prince Alfred Hospital, Sydney) was 
prospectively collected. A case-controlled study of all patients that received TAVI procedures, with 
and without the use of ECMO, was performed. Approval for the study was granted by the Sydney 
Local Health District Ethics Review Committee (RPAH zone). VA ECMO was classified into either: 
prophylactic ECMO, where usage was planned prior to the procedure; or rescue ECMO, where ECMO 
was emergently instituted for rescue from intraoperative complications. Other endpoints were defined 
using the updated Valve Academic Research Consortium Guidelines (VARC2) [2].
Patients
Between June 2009 and June 2013, 100 TAVI procedures were performed: 68 by a transfemoral 
approach, and 32 by a transapical (TA) approach [3]. The first nine patients received an Edward 
SAPIEN (ES) valve, then 89 patients received an ES-XT valve and two patients received a Medtronic 
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CoreValve. VA ECMO was used in a total of 11 (11%) patients, which included four TF patients 
(5.9% of all TF patients) and seven TA patients (21.9% of all TA patients). Of these 11 ECMO 
patients, eight (72.7%) received prophylactic ECMO and three (27.3%) required rescue ECMO. The 
reasons for using rescue ECMO in three patients were: two patients developed ventricular fibrillation 
(VF) after valvuloplasty resulting in cardiogenic shock that could not be promptly cardioverted; and 
one experienced an aortic annulus rupture and tamponade causing rapid haemodynamic collapse (the 
management and outcome of this patient has been previously reported in detail [4]). The decision to 
use prophylactic ECMO in 11 patients was made between the cardiothoracic surgeon, cardiologist, and 
anaesthetist. The criteria included a combination of: 
1. Heart failure requiring hospitalisation and stabilisation pre-TAVI
2. Pre-operative assessment of moderate or severe left and/or right ventricular failure
3. Haemodynamic instability during BAV performed to improve heart function pre-TAVI
4. Borderline haemodynamics at procedure with central venous pressure/pulmonary capillary 
wedge pressure >20mmHg, mean pulmonary artery pressure >40mmHg, and cardiac index 
<2.0 with no improvement on inotropes.
Operative Method
TAVI at our institution is performed by a ‘Heart Team’, which is a joint approach between 
cardiologists, cardiac surgeons, anesthetists, perfusionists, and others [5]. The method used to perform 
transfemoral and transapical TAVI with an ES valve has been described [6]. A transfemoral-first 
approach to TAVI was used. If transfemoral access was contraindicated due to small, atherosclerotic 
or tortuous iliofemoral or aortic vessels then transapical access was used. VA ECMO was established 
percutaneously via cannulation of the femoral or jugular vein for outflow and axillary or femoral 
arteries for inflow. The ECMO circuit consisted of Jostra Rotaflow (Jostra AG, Hirrlingen, Germany) 
centrifugal pump with a Quadrox D oxygenator. After cannulation the circuit was primed with 
crystalloid solution, anticoagulation achieved with heparin, and extracorporeal blood flow was 
established. Flows were initiated at 60-100cc/kg/min and increased if required.
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Statistical Analysis
Statistical analysis was performed with R (R Core Team, Vienna, Austria). The difference in baseline 
characteristics and postoperative outcomes between patients receiving any or no ECMO, and 
prophylactic or rescue ECMO were tested. Differences in the means of continuous variables were 
tested via the use of an independent samples t-test, while proportional differences in categorical 
variables were tested via the use of a Chi-square (2) test of independence. Significant mean 
differences in perioperative outcomes were additionally submitted to logistic regression to investigate 
whether differences were predicted by ECMO status (any or none), while controlling for preoperative 
surgical risk, represented by EuroSCORE.
Results
Baseline Patient Characteristics
Baseline patient characteristics and the difference between ECMO and non-EMCO patients are 
presented in Table 1. EuroSCORE was significantly higher for ECMO than non-ECMO patients (51.7 
± 24.9% vs. 30.8 ± 21.3%, p<.05). ECMO patients had significantly higher mean pulmonary artery 
pressure (39.4 ± 10.7mmHg vs. 30.4 ± 9.2mmHg, p<.05), were more likely to have pulmonary artery 
systolic pressure ≥ 60mmHg (67% vs. 20%, p<.01), and were more likely to have right ventricular 
dysfunction (either mild, moderate or severe) (55% vs. 3%, p<.01). These differences were expected, 
as they were used as primary indications for ECMO support. ECMO patients also had lower mean and 
peak transaortic gradients (39.7 ± 7.7mmHg vs. 46.0 ± 12.5mmHg, p<.05; and 59.8 ± 14.1mmHg vs. 
76.9 ± 19.7mmHg, p<.01 respectively), as well as significantly lower left ventricular ejection fraction 
(LVEF) (38.8 ± 17.5% vs. 61.3 ± 12.9%, p<.01).
Perioperative Outcomes
The descriptive statistics and proportional difference between ECMO and non-ECMO patients are 
presented in Table 2. In general, perioperative outcomes were similar between ECMO and non-ECMO 
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patients. Valve migration or malpositioning, and VT or VF post-pacing were significantly more likely 
in ECMO patients as they were indications for rescue ECMO.
The rate of 30-day all-cause mortality was nil (0%) in the prophylactic ECMO patients, one (33%) in 
rescue ECMO patients, one (9%) in ECMO (prophylactic or rescue) patients, two (2%) in non-ECMO 
patients, and three (3%) for the series in total. The difference between ECMO and non-ECMO patients 
was not significantly different (9% vs. 2% p>.05). The one early mortality in the ECMO group was a 
patient that required rescue ECMO for rapid haemodynamic collapse after transfemoral TAVI 
implantation that was the result of aortic annulus rupture and tamponade. Emergent surgical drainage 
of the effusion was performed via left thoracotomy. Then a valve-in-valve implantation was 
performed which successfully sealed the annular leak, however the patient died on postoperative day 3 
from systemic ischaemic complications [4]. The two early deaths in the non-ECMO group were a 
patient who died on postoperative day 25 from acute adrenal insufficiency after inadvertent chronic 
steroidal therapy suspension, and another patient who died on postoperative day 15 from 
complications related to the implantation (stroke, aspiration pneumonia).
In this series 11 (11%) patients developed acute renal failure (ARF) postoperatively: three rescue 
ECMO patients (100%), one prophylactic ECMO patient (12%), and seven (8%) non-ECMO patients. 
The results revealed that ECMO patients were significantly more likely to develop this complication 
than non-ECMO patients (36% vs. 8%, p<.05). The result held even after controlling for preoperative 
surgical risk (EuroSCORE) in logistic regression (exp[b] = 5.08, p<.05). This difference also emerged 
as significantly more likely to occur in rescue than prophylactic ECMO patients (100% vs. 12%, 
p<.05). Indeed all three rescue ECMO patients experienced this outcome. One (33%) of the rescue 
ECMO patients and four (57%) of the non-ECMO patients had preoperative renal insufficiency 
(creatinine >110μmol/L). 
Discussion
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The present experience underscores how VA ECMO can be used to provide cardiorespiratory support 
during TAVI, in both prophylactic and emergent settings. TAVIs are performed at our institution by a 
Heart Team that involves close collaboration with anaesthetists and perfusionists to facilitate 
appropriate bail-out options in the event of complications. We prefer ECMO to a full cardiopulmonary 
bypass (CPB) circuit for reasons of space, reduced circuit prime, reduced activated clotting time 
requirement, and ease of use.
Multiple intraoperative complications can result in refractory low cardiac output or cardiogenic shock 
during TAVI, including spontaneous or post-pacing VF or VT, inadequate coronary artery perfusion 
due to low intra-aortic pressure or coronary ostia obstruction by the prosthesis, aortic root rupture 
causing tamponade, or severe bradycardia or AV block from prosthesis impingement on the 
conduction system following deployment. Additionally, patients with preexisting severe left or right 
ventricular dysfunction with pulmonary hypertension may not tolerate pacing during BAV or 
prosthesis implantation, resulting in haemodynamic collapse. If the underlying problem is not able to 
be resolved promptly and cardiac output does not respond to pharmacological management then a 
number of options are available as a bridge-to-recovery, including ventricular assist devices and 
ECMO [7,8]. At our institution no patient leaves the TAVI operating theatre whilst still on ECMO, as 
long-term ECMO in such a high-risk and elderly population has not been shown to change outcome. 
The use of VA ECMO for rescue of cardiogenic shock is being increasingly studied. A 2013 
systematic review of ECMO in the context of refractory cardiac arrest concluded that in-hospital 
survival rates vary greatly from 6–59%, largely due to differences in patient selection [9]. Recently 
Kim and colleagues retrospectively reviewed 27 patients that required rescue ECMO for acute 
myocardial infarction complicated by cardiogenic shock: 82% of these patients were successfully 
weaned off ECMO, and 59% survived to discharge [10]. In the post-ECMO period 37% developed 
acute renal failure, and 37% developed pneumonia. They also found that a shorter period between
CPR initiation and ECMO commencement resulted in better chance of successful weaning off ECMO 
(p=0.006), and that earlier weaning from ECMO yielded better outcomes. Lazzeri and colleagues’ 
systematic review also found that outcomes depend heavily on the expertise of ECMO team [9].
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In this series one patient experienced intraoperative cardiac tamponade as a result of aortic root 
rupture, that required rescue with ECMO. TAVI patients with bulky calcific leaflets and fragile tissue 
are particularly susceptible to aortic root injury during BAV or prosthesis implantation. Other possible 
causes of tamponade include injury to the right ventricle from perforationof the transient pacemaker 
wire, and injury to the left ventricle from stiff guide wires and catheters. In these patients if 
haemodynamic stability cannot be restored with pericardiocentesis or emergent sternotomy then 
rescue ECMO can be instituted until the issue is resolved. The valve should be deployed under ECMO 
cover and then the patient slowly weaned.
The analysis revealed that ECMO patients were significantly more likely to develop ARF than non-
ECMO patients (36% vs. 8%, p<.05), especially if the ECMO was emergently instituted. Of the three 
rescue ECMO patients, two had VF post-pacing and thus experienced a period of systemic and renal 
hypoperfusion, which could have resulted in the ARF. ARF was also less common in prophylactic 
ECMO vs. rescue ECMO patients (p<.05), which suggests implementing ECMO before the need for 
rescue may help avoid this detrimental outcome. Other reasons for using rescue ECMO, including 
prosthesis migration, malpositioning, or aortic rupture, may require extra contrast usage which could 
also contribute to ARF. Another contributing factor was the incidence of the preoperative renal 
insufficiency, which was relatively common in the entire study population (55% of ECMO patients, 
and 52% of non-ECMO patients). A 2013 meta-analysis of 1,866 patients who received ECMO for 
cardiogenic shock found a cumulative rate of 55.6% of acute kidney injury (95% CI: 35.5 - 74.0%) 
(although studies used different definitions), and 46.0% of renal replacement therapy (95% CI: 36.7 -
55.5%) [11]. 
In this series the rate of early mortality at 30 days postoperatively was 9% in ECMO patients, 2% in 
non-ECMO patients, and 3% for the series in total. This is despite very high-risk patients: the mean 
EuroSCORE was 51.7 ± 24.9% in the ECMO patients and 30.8 ± 21.3% in the non-ECMO patients. 
Before and after controlling for this risk the rate of early mortality between the two groups was 
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similar. This early mortality rate is low compared to other reported studies: A 2013 meta-analysis 
comparing TAVI (n=1,688) to SAVR (n=1,777) found an all-cause mortality rate of 7.5% in TAVI 
patients [12]. Additionally, Husser and colleagues reported a rate of 22% in ECMO patients, which 
was significantly higher than their 5% rate in non-ECMO patients (p = .005) [13]. Their median 
logistic EuroSCORE was 26% (range 18–41) and 15% (range 9–22), respectively.
Our use of ECMO in the highest-risk cases was also much higher than reported in other TAVI series. 
Webb and colleagues reported that 4.1% of patients needed haemodynamic support in the Canadian 
series of 345 TAVI patients: 0.9% received haemodynamic support with intra-aortic balloon pump, 
2.9% with ECMO, and 0.3% with both [14]. The reasons for haemodynamic support were all 
emergent: acute severe left ventricular dysfunction (2.9%), ventricular apical bleeding (0.9%), and 
cardiac perforation (0.3%), which may explain why haemodynamic support was significantly 
associated with higher 30 day mortality (OR: 6.8, 95% CI: 2.0-22.9, p = 0.002) and late mortality (HR: 
2.6, 95% CI: 1.1-6). Additionally the IABP-SHOCKII trial has demonstrated that intra-aortic balloon 
pumps in patients with cardiogenic shock whilst undergoing revascularisation for myocardial
infarction does not improve survival at 12 months (51.8% vs. 51.4%, p=0.91) [15].
Evidently the risk of providing prophylactic ECMO is much less than requiring emergent rescue with 
ECMO. As such, the low rate of early mortality during the early phase of our TAVI program may 
have been in part due to our high rate of prophylactic ECMO usage in the highest-risk patients (the 
mean EuroSCORE was 51.7 ± 24.9%). An example of this are two patients in this series who were on 
low-flow prophylactic ECMO support and experienced VT post-pacing, so ECMO flows were able to 
be increased and thus the patients experienced no circulatory arrest until cardioversion. Other 
published evidence for the reduction of early mortality or morbidity through the usage of prophylactic 
ECMO is thus far limited. Husser and colleagues used rescue ECMO in eight out of 131 cases for 
cardiogenic shock, VT and ventricular perforation [13]. After this they used prophylactic ECMO in 
nine high-risk patients, which resulted in higher procedural success (100% vs. 44% p=0.03) and lower 
early mortality (0% vs. 44% p=0.02), and similar rates of major vascular complications (11% vs. 11%, 
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p=0.99) or life-threatening bleeding (11% vs. 33%, p=0.3) [13].
Drews and colleagues reported using elective normothermic CPB in high-risk patients (EuroSCORE I 
65 ± 23%) for similar reasons to our study, including preoperative cardiogenic shock (53%), severely 
depressed LV (37%) or RV (5%) function and pulmonary hypertension with enlarged RV (5%) [16]. 
Their strategy involved: placing the CPB tubes on the table in patients with pulmonary hypertension to 
save time if needed; to prophylactically cannulate the femoral vessels in patients with severely 
depressed LVEF (<25%) but only start CPB if they became unstable; and to perform valvuloplasty and 
valve deployment under a short run of CPB in patients with poor LV performance (LVEF 10–20%), 
cardiogenic shock or decompensated right-sided heart failure with an enlarged RV. The overall 30-day 
mortality rate in their cohort was 14%, all of which occurred in patients with preoperative cardiogenic 
shock, and was thus relatively low. The one- and two-year survival rates were 57 ± 8.4 and 49 ± 10%, 
respectively, and also significantly worse in those with cardiogenic shock [16].
Therefore, in our view this evidence suggests that prophylactic ECMO should be used more rather 
than less in the highest-risk patients, and we are looking prospectively to a create a defined scoring 
system to determine which patients receive prophylactic ECMO in TAVI at our institution.
Limitations
This study has a number of important limitations. As mentioned there was a small sample size of 
ECMO patients and thus it is difficult to draw definite conclusions from results. The study was also 
observational in nature. Whilst every effort was made to ensure data completeness and accuracy, some 
endpoints were missing small amounts of data, which was accounted for during the analysis. 
Conclusion
ECMO, in both prophylactic and rescue settings, is effective at providing cardiorespiratory support in 
very-high risk TAVI patients, and may have contributed to the low mortality in this series. Instituting 
prophylactic ECMO in an elective, controlled setting may help avoid consequences of intraoperative 
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complications such as systemic hypoperfusion and ARF, compared to emergent ECMO with rapid 
setup and cannulation. In this clinical study, the criteria used to institute prophylactic ECMO were pre-
operative assessment of moderate or severe left and/or right ventricular failure, difficulty with BAV 
performed to improve heart function pre-TAVI, and borderline haemodynamics at procedure. Future 
studies performed in a prospective, randomised fashion are required to evaluate the use of prophylactic 
ECMO, and to determine the ideal selection criteria.
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Tables
Table 1: Baseline characteristics of patients who received ECMO.
Prophylactic 
ECMO
Rescue
ECMO
ECMO 
(combined) Non-ECMO
(n = 8) (n = 3) (n = 11) (n = 89)
ECMO vs. 
Non-ECMO 
Differencea
Logistic EuroSCORE I (%) 49.29 ± 24.65 58.24 ± 29.98 51.73 ± 24.95 30.81 ± 21.32 20.92*
Age (yrs) 75.62 ± 10.01 76.00 ± 8.00 75.73 ± 9.11 83.52 ± 8.55 -7.79*
Male 6 (75%) 2 (67%) 8 (73%) 55 (62%) 11%
Body mass index (kg/m2) 25.51 ± 1.97 31.67 ± 8.93 27.56 ± 5.64 26.05 ± 4.94 1.51
NYHA class III or IV 8 (100%) 3 (100%) 11 (100%) 74 (83%) 0.17
Moderate-severe lung disease 0 (0%) 2 (67%) 2 (18%) 10 (11%) 0.07
History of smoking 6 (75%) 2 (67%) 8 (73%) 55 (62%) 0.11
Hypertension 8 (100%) 3 (100%) 11 (100%) 77 (87%) 0.13
Hyperlipidaemia 4 (50%) 2 (67%) 6 (55%) 43 (48%) 0.07
Diabetes mellitus 3 (38%) 0 (0%) 3 (27%) 14 (16%) 0.11
Previous myocardial infarction 6 (75%) 2 (67%) 8 (73%) 23 (26%) 47%**
Previous CABG 6 (75%) 3 (100%) 9 (82%) 30 (34%) 48%**
Previous PCI 1 (12%) 0 (0%) 1 (9%) 28 (31%) -0.22
Previous balloon aortic valvuloplasty 4 (50%) 0 (0%) 4 (36%) 17 (19%) 0.17
Cerebrovascular disease 2 (25%) 2 (67%) 4 (36%) 24 (27%) 0.09
Peripheral vascular disease 2 (29%) 2 (67%) 4 (40%) 26 (29%) 0.11
Renal insufficiencyb 5 (62%) 1 (33%) 6 (55%) 46 (52%) 0.03
Patients on dialysis 1 (12%) 0 (0%) 1 (9%) 4 (4%) 0.05
Atrial fibrillation 0.25 ± 0.46 0.00 ± 0.00 0.18 ± 0.40 0.36 ± 0.48 -0.18
Echocardiography
Mean transaortic gradient (mmHg) 40.14 ± 9.30 38.67 ± 1.53 39.70 + 7.66 45.96 ± 12.52 -6.26*
Peak transaortic gradient (mmHg) 58.86 ± 17.03 62.00 ± 4.36 59.80 ± 14.14 76.94 ± 19.72 -17.14**
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Aortic valve area (cm2) 0.64 ± 0.13 0.63 ± 0.06 0.64 ± 0.11 0.73 ± 0.23 -0.09†
LVEF (%) 32.33 ± 7.47 58.00 ± 29.70 38.75 ± 17.52 61.25 ± 12.95 -22.50**
Mean PA pressure 40.71 ± 10.58 35.00 ± 14.14 39.44 ± 10.74 30.42 ± 9.20 9.03*
Systolic PA pressure ≥60mmHg 4 (57%) 2 (100%) 6 (67%) 14 (20%) 47%**
Right ventricular dysfunction 4 (50%) 2 (67%) 6 (55%) 3 (3%) 52%**
Mild 2 (25%) 1 (33%) 3 (27%) 2 (2%)
Moderate 2 (25%) 1 (33%) 3 (27%) 0 (0%)
Severe 0 (0%) 0 (0%) 0 (0%) 1 (1%)
Descriptive Statistics presented as n (%) or mean ± standard deviation as appropriate. NYHA = New York Heart 
Association; CABG = Coronary Artery Bypass Graft; PCI = Percutaneous Coronary Intervention; PA = 
Pulmonary artery; LVEF = Left ventricular ejection fraction
**p < .01, * p < .05, † p < .10
aTest is t-test for continuous variable; Chi-Square for categorical
bdefined as creatinine >100μmol/L
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Table 2: Perioperative  outcomes of patients who received ECMO.
Prophylactic 
ECMO
Rescue 
ECMO
ECMO 
(combined) Non-ECMO
(n = 8) (n = 3) (n = 11) (n = 89)
ECMO vs. 
Non-ECMO 
Differencea
Intraoperative outcomes
Conversion to open procedure 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0%
Valve migration or 
malpositioning 1 (12%) 1 (33%) 2 (18%) 2 (3%) 15%
Coronary ostia obstruction 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0%
VT/VF post pacing 2 (25%) 2 (67%) 4 (36%) 2 (2%) 34%**
Delayed closure 1 (12%) 0 (0%) 1 (9%) 1 (1%) 8%
30 day outcomes
All-cause mortality 0 (0%) 1 (33%) 1 (9%) 2 (2%) 7%
Cardiovascular mortality 0 (0%) 1 (33%) 1 (9%) 1 (1%) 8%
Peri-procedural MI (<72hrs) 0 (0%) 0 (0%) 0 (0%) 2 (2%) -2%
Spontaneous MI (>72hrs) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0%
Disabling Stroke 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0%
Non-disabling Stroke 0 (0%) 0 (0%) 0 (0%) 2 (2%) -2%
Transient ischaemic attack 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0%
Life-threatening bleeding 1 (12%) 1 (33%) 2 (18%) 3 (3%) 15%
Major bleeding 0 (0%) 1 (33%) 1 (9%) 10 (12%) -3%
Minor bleeding 3 (38%) 0 (0%) 3 (27%) 11 (13%) 14%
Acute renal failure 1 (12%) 3 (100%)b 4 (36%) 7 (8%) 28%*
Major vascular complications 1 (12%) 1 (33%) 2 (18%) 4 (5%) 13%
Minor vascular complications 0 (0%) 0 (0%) 0 (0%) 11 (13%) -13%
Need for permanent pacemaker 2 (25%) 1 (33%) 3 (27%) 12 (13%) 14%
Postoperative atrial fibrillation 1 (12%) 0 (0%) 1 (9%) 5 (6%) 3%
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Descriptive Statistics presented as n (%). MI = Myocardial Infarction.
**p < .01, * p < .05, † p < .10
aChi-Square test
bp(Rescue = Support) < .05
